CBS 2019
CBSMD教育中心
中 文

充血性心力衰竭

Abstract

Recommended Article

Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction Percutaneous Atriotomy for Levoatrial–to–Coronary Sinus Shunting in Symptomatic Heart Failure: First-in-Human Experience Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF) Permanent pacemaker use among patients with heart failure and preserved ejection fraction: Findings from the Acute Decompensated Heart Failure National Registry (ADHERE) National Registry Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

Original Research2020 Jul 18.

JOURNAL:ESC Heart Fail. Article Link

Circulating sST2 and catestatin levels in patients with acute worsening of heart failure: a report from the CATSTAT-HF study

JA Borovac, D Glavas, ZS Grabovac et al. Keywords: acute decompensated heart failure; catestatin; HF; hospital mortality; risk stratification; soluble suppression of tumourigenicity

Full Text PDF